Quotes delayed, except where indicated otherwise. Currency in GBp.
Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12,000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.
Cambridge, UK, 26 September 2017: Horizon Discovery Group plc (LSE: HZD), (“Horizon” or “the Group”), a global leader in gene …
On track to meet revenue guidance for the enlarged Group of £37-£41 million for FY2017, with strong H2 order book …
Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research Access to CRISPR for the …
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the international life sciencetools business today announces a trading update …
Cambridge, UK, 25 November 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and …
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth Expansion of …
|Operating Profit / (Loss)||(5,350)||(10,290)|
|Profit / (Loss) before tax||(6,073)||(10,540)|
|Cash & cash equivalents||18,215||25,067|
“The new science of personalised medicine” (PWC report 2011).
Currently, the total US market for personalised medicine and healthcare (wide, by definition) is estimated at £149bn and is projected to surpass £288bn by 2015
The core diagnostic and therapeutic segment (pharmaceuticals, medical device and diagnostic companies) is estimated at £15bn, with an estimated annual growth rate of c.10%, to reach £27bn by 2015.
30% of all pharma companies now require research & development compounds to have a patient-relevant biomarker
Investor’s Chronicle (17 Apr 2015)
“Final Results out this week revealed that the Co had outperformed expectations, with full year revenues rising to £11.9m, 8% ahead of consensus estimates. BUY”
Mail on Sunday (23 Mar 2015)
“Discover the life science firm that will broaden your horizons.”
Shares (Dec 2014)
“15 for 2015: Horizon Discovery”
Panmure Gordon (House Broker)
“Horizon offers investors a rare opportunity to gain exposure to an enabling healthcare company operating a unique and enabling technology platform within its chosen markets.”